Estrella Immunopharma(ESLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ESLA Estrella Immunopharma

Pre-Market Trading 03-26 06:50:40 EDT

0.9999

+0.0101

+1.02%

High0.9999	Low0.9400	Vol1.72K
Open0.9400	D1 Closing0.9898	Amplitude6.05%
Mkt Cap36.18M	Tradable Cap9.92M	Total Shares36.18M
T/O1.69K	T/O Rate0.02%	Tradable Shares9.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ESLA","market":"US","secType":"STK","nameCN":"Estrella Immunopharma","latestPrice":0.9999,"timestamp":1742932800000,"preClose":0.9898,"halted":0,"volume":1716,"delay":0,"floatShares":9925676,"shares":36179147,"eps":-0.245674,"marketStatus":"Pre-Market Trading","change":0.0101,"latestTime":"03-26 06:50:40 EDT","open":0.94,"high":0.9999,"low":0.94,"amount":1687.011851,"amplitude":0.060517,"askPrice":1.16,"askSize":200,"bidPrice":0.8322,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.245674,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1742995800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1,"postHourTrading":{"tag":"盘后","latestPrice":1,"preClose":0.9999,"latestTime":"16:00 EDT","volume":72,"amount":72,"timestamp":1742932802204},"volumeRatio":0.11638158952229247},"requestUrl":"/m/hq/s/ESLA","defaultTab":"news","newsList":[{"id":"2513902012","title":"Estrella Immunopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2513902012","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513902012?lang=en_us&edition=full_marsco","pubTime":"2025-02-22 00:58","pubTimestamp":1740157080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 21, 2025 11:58 ET (16:58 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA"],"gpt_icon":0},{"id":"2513924812","title":"Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2513924812","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513924812?lang=en_us&edition=full_marsco","pubTime":"2025-02-22 00:10","pubTimestamp":1740154215,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma (ESLA) said Friday it has completed the first dose group in its ongoing phase I/II clinical trial evaluating EB103 in adult patients with relapsed/refractory B-cell non-Hodgkin l","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2513129368","title":"BRIEF-Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2513129368","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513129368?lang=en_us&edition=full_marsco","pubTime":"2025-02-21 22:08","pubTimestamp":1740146889,"startTime":"0","endTime":"0","summary":"BRIEF-Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose CohortFeb 21 (Reuters) - Estrella Immunopharma Inc ESLA.O:ESTRELLA IMMUNOPHAR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nFWN3PC0YM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2513298026","title":"Estrella Immunopharma completes first dose cohort in STARLIGHT trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2513298026","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513298026?lang=en_us&edition=full_marsco","pubTime":"2025-02-21 21:55","pubTimestamp":1740146136,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma (ESLA) announced the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. Fol...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-completes-first-dose-cohort-in-starlight-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-completes-first-dose-cohort-in-starlight-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2513260233","title":"Estrella Immunopharma Completes First Dose Cohort in Starlight-1 Trial and Receives Approval to Initiate Higher Dose Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2513260233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513260233?lang=en_us&edition=full_marsco","pubTime":"2025-02-21 21:30","pubTimestamp":1740144638,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nFWN3PC0YM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2513298565","title":"Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2513298565","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513298565?lang=en_us&edition=full_marsco","pubTime":"2025-02-21 21:30","pubTimestamp":1740144600,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., February 21, 2025----Estrella Immunopharma, Inc.  , a clinical stage biopharmaceutical company developing CD19-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. Following a review of safety and efficacy data, the Data and Safety Monitoring Board  has approved the initiation of the second dose cohort, which will administer 5 million receptor-positive T cells per kilogram of body weight of EB103 CD19-Redirected ARTEMIS T-cell therapy.Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Estrella’s mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and other diseases. To accomplish this mission, Estrella’s lead product candidate, EB103, utilizes Eureka’s ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/estrella-immunopharma-completes-first-dose-133000768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ESLAW","ESLA"],"gpt_icon":0},{"id":"2512305394","title":"Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2512305394","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512305394?lang=en_us&edition=full_marsco","pubTime":"2025-02-20 05:46","pubTimestamp":1740001560,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., February 19, 2025----Estrella Immunopharma, Inc.  , a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, today announced that D. Boral Capital LLC , a leading investment bank, has initiated coverage on the Company, assigning a Buy rating to Estrella and established a 12-month price target of $16.00.D. Boral Capital’s analysis focuses on the development of EB103 in B-cell Non-Hodgkin’s Lymphoma, emphasizing Estrella’s ARTEMIS T-cell engineering platform that utilizes cellular mechanisms which closely resemble those of endogenous T-cell receptors, producing a more natural and regulated immune response.The derived 12-month price target of $16.00 underscores market confidence in Estrella’s potential to capture significant market share in immuno-oncology.The models incorporate a 30% probability of success along with a 30% discount rate, reflecting the early stage of Estrella’s clini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/estrella-immunopharma-inc-nasdaq-esla-214600801.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","ESLA","ESLAW",".IXIC"],"gpt_icon":0},{"id":"2512417151","title":"Estrella Immunopharma Initiated at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2512417151","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512417151?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 20:21","pubTimestamp":1739881260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 07:21 ET (12:21 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2512151669","title":"Estrella Immunopharma initiated with a Buy at D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2512151669","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512151669?lang=en_us&edition=full_marsco","pubTime":"2025-02-18 20:16","pubTimestamp":1739881005,"startTime":"0","endTime":"0","summary":"D. Boral Capital analyst Jason Kolbert initiated coverage of Estrella Immunopharma (ESLA) with a Buy rating and $16 price target The firm says Estr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-initiated-with-a-buy-at-d-boral-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-initiated-with-a-buy-at-d-boral-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2492464087","title":"BRIEF-Estrella Immunopharma Inc - Regains Compliance With Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492464087","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492464087?lang=en_us&edition=full_marsco","pubTime":"2024-12-17 05:04","pubTimestamp":1734383082,"startTime":"0","endTime":"0","summary":"Dec 16 (Reuters) - Estrella Immunopharma Inc   :   * ESTRELLA IMMUNOPHARMA INC - REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","QLD","TQQQ","USAW.SI","TSYW.SI",".IXIC","BK4588","IE00B3QW5Z07.USD","MNQmain","IE00BKPKM429.USD","LU2095319765.USD","SQQQ","NDAQ","BK4112","USJW.SI","BK4585","LU2210150020.SGD","IE00B64PRP62.GBP","ESLA","BK4139","PSQ","NVIW.SI","LU2210149790.SGD","QID","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2492647746","title":"Estrella Immunopharma Inc - Regains Compliance With Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492647746","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492647746?lang=en_us&edition=full_marsco","pubTime":"2024-12-17 05:01","pubTimestamp":1734382903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NH0QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2491688093","title":"Estrella Immunopharma files $100M common stock, warrants offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2491688093","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491688093?lang=en_us&edition=full_marsco","pubTime":"2024-12-13 06:15","pubTimestamp":1734041711,"startTime":"0","endTime":"0","summary":"17:11 EST Estrella Immunopharma (ESLA) files $100M common stock, warrants offering Published first on TheFly – the ultimate source for real-time, m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-files-100m-common-stock-warrants-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-files-100m-common-stock-warrants-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2491350796","title":"Estrella Immunopharma : May Offer, Sell up to $100 Mln of Common Stock, Warrants From Time to Time in One or More Transactions","url":"https://stock-news.laohu8.com/highlight/detail?id=2491350796","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491350796?lang=en_us&edition=full_marsco","pubTime":"2024-12-13 06:11","pubTimestamp":1734041504,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nFWN3ND126:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2489235607","title":"BRIEF-Estrella Immunopharma Entered Amendment No. 2 To Common Stock Purchase Agreement Dated April 20, 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2489235607","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489235607?lang=en_us&edition=full_marsco","pubTime":"2024-12-06 22:17","pubTimestamp":1733494674,"startTime":"0","endTime":"0","summary":"Dec 6  - Estrella Immunopharma Inc   :   * ESTRELLA IMMUNOPHARMA: ENTERED AMENDMENT NO. 2 TO COMMON STOCK PURCHASE AGREEMENT DATED APRIL 20, 2023   * ESTRELLA IMMUNOPHARMA-PURSUANT TO AMENDMENT, CO MAY SELL AND ISSUE UP TO $50 MILLION OF ITS COMMON STOCK TO WHITE LION FROM TIME TO TIME   * ESTRELLA IMMUNOPHARMA INC - PURCHASE AGREEMENT TERM EXTENDED TO DECEMBER 30, 2025Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2489423562","title":"Estrella Immunopharma-Pursuant to Amendment, Co May Sell and Issue up to $50 Mln of Its Common Stock to White Lion From Time to Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2489423562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489423562?lang=en_us&edition=full_marsco","pubTime":"2024-12-06 22:14","pubTimestamp":1733494456,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nFWN3N71E7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2489235627","title":"Estrella Immunopharma Inc - Purchase Agreement Term Extended to December 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2489235627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489235627?lang=en_us&edition=full_marsco","pubTime":"2024-12-06 22:14","pubTimestamp":1733494456,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nFWN3N71E7:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2489235622","title":"Estrella Immunopharma: Entered Amendment No. 2 to Common Stock Purchase Agreement Dated April 20, 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2489235622","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489235622?lang=en_us&edition=full_marsco","pubTime":"2024-12-06 22:14","pubTimestamp":1733494456,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nFWN3N71E7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2486856368","title":"BRIEF-Estrella Immunopharma Changes Fiscal Year End To December 31","url":"https://stock-news.laohu8.com/highlight/detail?id=2486856368","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486856368?lang=en_us&edition=full_marsco","pubTime":"2024-11-27 07:08","pubTimestamp":1732662532,"startTime":"0","endTime":"0","summary":"Nov 26 (Reuters) - Estrella Immunopharma Inc   :   * ESTRELLA IMMUNOPHARMA INC - CHANGES FISCAL YEAR END TO DECEMBER 31Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2486685551","title":"Estrella Immunopharma Inc - Changes Fiscal Year End to December 31","url":"https://stock-news.laohu8.com/highlight/detail?id=2486685551","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486685551?lang=en_us&edition=full_marsco","pubTime":"2024-11-27 06:49","pubTimestamp":1732661354,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nFWN3MX0ZO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESLA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.estrellabio.com","stockEarnings":[{"period":"1week","weight":0.0988},{"period":"1month","weight":-0.3244},{"period":"3month","weight":-0.1463},{"period":"6month","weight":0.0309},{"period":"1year","weight":-0.1151},{"period":"ytd","weight":-0.1667}],"compareEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":-0.0408},{"period":"3month","weight":-0.043},{"period":"6month","weight":0.0055},{"period":"1year","weight":0.1071},{"period":"ytd","weight":-0.0181}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":-0.019009},{"month":2,"riseRate":0.5,"avgChangeRate":-0.025426},{"month":3,"riseRate":0.5,"avgChangeRate":0.044126},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.046969},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.031798},{"month":6,"riseRate":0.666667,"avgChangeRate":0.039731},{"month":7,"riseRate":0.666667,"avgChangeRate":0.139894},{"month":8,"riseRate":0,"avgChangeRate":-0.155794},{"month":9,"riseRate":0.666667,"avgChangeRate":0.067027},{"month":10,"riseRate":0.5,"avgChangeRate":-0.283282},{"month":11,"riseRate":1,"avgChangeRate":0.121807},{"month":12,"riseRate":0.25,"avgChangeRate":-0.071717}],"exchange":"NASDAQ","name":"Estrella Immunopharma","nameEN":"Estrella Immunopharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Estrella Immunopharma(ESLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Estrella Immunopharma(ESLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Estrella Immunopharma,ESLA,Estrella Immunopharma股票,Estrella Immunopharma股票老虎,Estrella Immunopharma股票老虎国际,Estrella Immunopharma行情,Estrella Immunopharma股票行情,Estrella Immunopharma股价,Estrella Immunopharma股市,Estrella Immunopharma股票价格,Estrella Immunopharma股票交易,Estrella Immunopharma股票购买,Estrella Immunopharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Estrella Immunopharma(ESLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Estrella Immunopharma(ESLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction